Adagene (ADAG) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed NervGen Pharma (NGEN) over the past year, gaining 42.2% versus a loss of 48.2%. Over five years, NGEN leads with a -7.4% price change compared with -76.0% for ADAG. NervGen Pharma is the larger company by market cap ($188.2 million vs $186.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | NGEN |
|---|---|---|
| Share price | $2.78 | $1.75 |
| Market cap | $186.66M | $188.16M |
| 1-day change | -1.07% | +0.57% |
| YTD return | +47.09% | -68.75% |
| 1-year return | +42.20% | -48.18% |
| 5-year return | -75.98% | -7.41% |
| EPS (TTM) | $-0.37 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $6.30 |
| 52-week low | $1.30 | $1.58 |
| Distance from 52-week high | -42.68% | -72.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +256.47% | +471.43% |
| Average volume | 244.76K | 565.19K |
| Shares outstanding | 67.14M | 107.52M |
| Employees | 128 | 9 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed NGEN by 90.4 percentage points over the past year.
- The two companies sit in different sectors: Adagene in Healthcare and NervGen Pharma in Health Care.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Healthcare · Biotechnology · 128 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
ADAG vs NGEN FAQ
Which is bigger, Adagene or NervGen Pharma?
NervGen Pharma (NGEN) is larger, with a market capitalization of $188.16M compared with $186.66M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or NGEN?
ADAG returned +42.20% over the past 12 months, compared with -48.18% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and NervGen Pharma in the same industry?
No. Adagene is in the Healthcare sector, while NervGen Pharma is in Health Care.